About 10 to 15 percent of children experience recurrent abdominal pain, the researchers said. The pain can be due to irritable bowel syndrome — which is usually relieved by defecation — or can be “functional abdominal pain,” which is not explained by another disease. While LGG has been tested before in children with abdominal pain, the studies were small and showed mixed results. The new study, which involved 141 children with irritable bowel syndrome or functional abdominal pain, was conducted in Italy between 2004 and 2008. Researchers gave the kids either the probiotic or a placebo for eight weeks. Neither the doctors nor the patients were aware which treatment they received.
Following the treatment, the patients were followed up for another 8 weeks. During the treatment and follow-up, the severity and frequency of abdominal pain decreased for both groups, but the probiotic group experienced a more drastic reduction. For instance, after 12 weeks, patients who took the probiotic reported experiencing, on average, 1.1 episodes of pain per week, compared with 3.7 weekly episodes before the treatment. Those who took the placebo reported experiencing 2.2 pain episodes per week, compared with 3.5 episodes initially.
And a greater percentage of parents of children who took the probiotic reported that their children experienced a decline in pain,compared with those whose kids took the placebo. Among kids who took the probiotic, it was mostly children with irritable bowel syndrome who showed improvements, the researchers said.
Why does it work?
The results suggest LGG may be specifically beneficial for those with irritable bowel syndrome, the researchers said. It's possible that children with irritable bowel syndrome have an imbalance of good and bad bacteria in their guts, which contributes to the pain, and the probiotics relieves pain by restoring the proper balance, Francavilla said. Probiotics have also been suggested to reduce inflammation in the gut, as well as stimulate the release of analgesic substances that relieve pain. The researchers noted they cannot be sure whether the beneficial effects will last for more than a few weeks after treatment is stopped.
The results were published in the journal Pediatrics.
The randomized, double-blind, placebo-controlled study, which was funded by The Dannon Company, Inc., involved 638 healthy children aged three to six, all of whom attended school five days a week. Parents were asked to give their child a strawberry yogurt-like drink every day. Some of the drinks contained the probiotic strain Lactobacillus casei (L. casei) and the others did not. Parents were also asked to record how many yogurt drinks their child consumed and to keep notes on their child's health.
At the end of the study, there was a 19 percent decrease in the number of common infections—e.g., ear infections, flu, diarrhea, sinusitis–among children who had consumed the yogurt drink with the probiotics than those who had the drink without the beneficial bacteria. When the researchers broke out the individual types of illness, they found that children who had the probiotic beverage had 24 percent fewer gastrointestinal infections (e.g., diarrhea, nausea, vomiting), and 18 percent fewer upper respiratory tract infections (e.g., ear, sinusitis, strep).
The reduction in infections did not, however, result in fewer days lost from school. Merenstein commented that “It is my hope that safe and tolerable ways to reduce illnesses could eventually result in fewer missed school days which means fewer work days missed by parents.”
The finding that the probiotic yogurt drink reduced infections in children, however, is significant. This joins results from other studies demonstrating benefits of probiotics in children, including one published in Pediatrics in which they reduced cold and flu symptoms, another in which they eased diarrhea, and one showing they helped prevent eczema in infants. Generally, probiotics have also been shown to benefit people who have celiac disease, irritable bowel, colitis, and possibly autism.
Georgetown University Medical Center
Metabolic syndrome (MetS) is a condition characterised by central obesity, hypertension, and disturbed glucose and insulin metabolism. The syndrome has been linked to increased risks of both type 2 diabetes and cardiovascular diseases.
Gut microflora and metabolic syndrome
“The recent discovery by our group that patients feeding a fat-enriched diet develop diabetes and obesity through changes of their intestinal microflora has led us to envision innovative strategies aiming to hamper the development of the deleterious intestinal bacterial ecology observed during metabolic diseases,” said Professor Remy Burcelin of INSERM, who led the study.
The current study involved administering the probiotic strain B420 to diabetic mice on a high-fat diet. According to the researchers, the probiotic improved the fasting glycaemia and restored the glucose turnover rate to the level of the control mice fed with normal chow.
“Importantly, the probiotic treatment reduced the fasted insulin levels, but improved the insulin secretion upon glucose challenge, indicating an improved metabolic flexibility and restoration of normal glucose metabolism, and a potential beneficial effect on metabolic syndrome,” said Danisco.
The company added that the beneficial effect of B420 is mediated by a reduction of the pro-inflammatory molecule, plasma lipopolysaccharide (LPS). “B420 changes intestinal mucosal microbiota and reduces the efflux of LPS into plasma, thereby reducing inflammation and improving insulin metabolism,” it said.
Probiotics and obesity
A breakthrough paper published in Nature in December 2006 reported that microbial populations in the gut are different between obese and lean people, and that when the obese people lost weight their microflora reverted back to that observed in a lean person, suggesting that obesity may have a microbial component.
More findings on the topic have since trickled through the scientific web. At a scientific symposium organised by the Beneo Group in April 2008, Dr. Kieran Touhy from the University of Reading noted that obese animals have significantly lower bifidobacteria levels than their lean counterparts, which suggests potential for prebiotic fibres since the growth of these bacteria is selectively promoted by inulin and fructooligosaccharides.
Dr. Nathalie Delzenne from the Catholic University of Louvain in Belgium and Dr. Robert Welch from the University of Ulster presented results from animal and human studies, respectively, which indicated the potential of prebiotic supplementation to regulated food intake.
“This is an interesting new research area which may open up new opportunities for functional foods in the future,” said Dr Julian Stowell, head of scientific affairs for Danisco's Health and Nutrition Platform.